A funny thing happened on the way to Medtronic's (NYSE: MDT )
presumed domination of the emerging $3 billion-a-year renal
denervation (RDN) market. RDN might not work ... or at least not nearly
as well as initially thought.
While the potential loss of a chunk of that $3 billion pie is not a model-breaker for Medtronic, St. Jude Medical (NYSE: STJ ) , Boston Scientific (NYSE: BSX ) , or Covidien (NYSE: COV ) , it is a good reminder that pilot studies and European approval don't always tell the whole story.
Read more here:
Medtronic's Surprising Update Spikes Blood Pressures Across Med-Tech
No comments:
Post a Comment